Home of
 

Keywords :   


Tag: of

We Dont Need 5G in Cars: Report Captures Car Cockpit Data Fight Over Adoption of DSRC using 802.11p vs Extension of Wi-FI

2016-12-05 21:08:21| AutomotiveDigest.com - Automotive Industry News

Situation or Why the Fight? Mobile Experts LLC has released a hard-hitting study. Report investigates connectivity for telematics, vehicle-to-vehicle. (V2V) and vehicle-to-infrastructure (V2I) applications using DSRC & LTE,7 wireless apps for cars. Suggests new biz models for insurance & 5G technology prospects Fight grew out of political battle raging within the auto industry Wireless industry-led by Qualcomm--pushing for extension of Wi-Fi Here is what the Report Contends: No Need for 5G in Cars Cars are already connected using 2G, 3G, and LTE. Authors say we don't see a role for 5G in the car. Predicts rise of new business models coming to the market. Such as Usage Based Insurance, fleet management, infotainment, & improved safety. Learn what this MEANS to the auto market, see PDF and Link ________________________________________________________________________ The Article We Dont Need 5G in Cars: Report Captures Car Cockpit Data Fight Over Adoption of DSRC using 802.11p vs Extension of Wi-FI appeared first on Automotive Digest.

Tags: of data report using

 

Updated KEYTRUDA (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology

2016-12-05 16:42:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, achieved an overall response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with follow-up of up to 27 months in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma, who were ineligible for or failed to respond to autologous stem-cell transplantation (ASCT). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: of large updated american

 
 

Tip of the Week: Run a Full Battery of Tests

2016-12-05 16:22:00| Electrical Construction & Maintenance

One test of your equipment might detect a problem, but to uncover all potential issues, you will need to conduct a full range of tests. read more

Tags: of full week run

 

Moldova pay TV subscribers down in first 9 months of 2016

2016-12-05 15:00:44| Digital TV News

Data submitted to Moldova's communications regulator, ANRCETI, for the country's pay TV market in the first nine months of 2016, shows that the IPTV segment continues to grow, while cable TV is in decline.

Tags: of months pay subscribers

 

BP approves Mad Dog Phase 2 project in Gulf of Mexico

2016-12-05 01:00:00| Offshore Technology

BP has approved the Mad Dog Phase 2 project located in the Gulf of Mexico, underlining the companys commitment in US despite the present low oil price environment.

Tags: of project mexico dog

 

Sites : [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] next »